Business Context and Reporting Period
This Form 8-K is filed by Conduit Pharmaceuticals Inc. (CDT) on October 9, 2024, reporting events occurring as of September 20, 2024, and October 11, 2024. The Company is an emerging growth company incorporated in Delaware with principal offices in San Diego, California.
Key Financial Metrics and Obligations
The filing details a specific debt obligation rather than general financial performance metrics.
- Debt Instrument: Convertible Promissory Note originally issued March 20, 2023, with a principal amount of $800,000.
- Interest Rate: 20% per annum.
- Original Maturity: September 20, 2024.
- Conversion Price: Fixed at $10.00 per share for principal conversion.
- Stock Issuance: On October 11, 2024, the Company issued 2,781,250 shares of Common Stock to satisfy accrued interest and a portion of the principal obligation.
Material Changes
The Company amended the Convertible Note on October 9, 2024, effective September 20, 2024, resulting in the following material changes:
- Extension of Maturity: The repayment date was extended to October 20, 2024, with an option for the Company to further extend the date to November 19, 2024, or December 19, 2024.
- Debt-to-Equity Conversion: The amendment required the issuance of shares to settle accrued interest and a portion of the principal prior to the new repayment date.
- Waiver of Immediate Payment: Interest and principal previously due were waived for immediate payment and rescheduled to the new Repayment Date.
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking guidance, management commentary on future operations, or a discussion of general risks beyond the specific terms of the debt amendment. The primary contingency noted is the Company's discretionary right to extend the repayment deadline further into late 2024.
Investor Verification Checklist
- Verify the exact closing market price used to calculate the $80,000 worth of shares issued for accrued interest.
- Confirm the remaining principal balance of the $800,000 note after the issuance of 2,000,000 shares.
- Monitor whether the Company exercises its option to extend the repayment date to November or December 2024.
- Review the dilution impact of the 2,781,250 newly issued shares on existing shareholders.